Bezafibrate after UDCA improves survival in PBC

Patients with primary biliary cholangitis who received bezafibrate after incomplete response to Ocaliva showed lower risk for death or liver transplant, according to a presenter at the Digital International Liver Congress.“Ursodeoxycholic acid [Ocaliva, Intercept] is a first-line treatment for primary biliary cholangitis. As you know, 20% to 30% of patients exhibit incomplete response to

Read the full article here

Related Articles